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Abstract. Background: High rates of antimicrobial resistance (AMR) in Neisseria gonorrhoeae hinder effective
treatment, but molecular AMR diagnostics may help address the challenge. This study aimed to appraise the literature for
resistance-associated genotypic markers linked to fluoroquinolones and macrolides, to identify and review their use in
diagnostics.Methods:Medline and EMBASE databases were searched and data pooled to evaluate associations between
genotype and phenotypic resistance. The minimum inhibitory concentration (MIC) cut-offs were  0.06 mg L1 for
non-resistance to ciprofloxacin and  0.5 mg L1 for non-resistance to azithromycin. Results: Diagnostic accuracy
estimates were limited by data availability and reporting. It was found that: 1) S91 and D95 mutations in the GyrA protein
independently predicted ciprofloxacin resistance and, used together, gave 98.6% (95% confidence interval (CI)
98.0–99.0%) sensitivity and 91.4% (95%CI 88.6–93.7%) specificity; 2) the number of 23S rRNA gene alleles with
C2611T or A2059G mutations was highly correlated with azithromycin resistance, with mutation in any allele giving a
sensitivity and specificity of 66.1% (95%CI 62.1–70.0%) and 98.9% (95%CI 97.5–99.5%) respectively. Estimated
negative (NPV) and positive predictive values (PPV) for a 23S rRNA diagnostic were 98.6% (95%CI 96.8–99.4%) and
71.5% (95%CI 68.0–74.8%) respectively; 3) mutation at amino acid position G45 in the MtrR protein independently
predicted azithromycin resistance; however, when combined with 23S rRNA, did not improve the PPV or NPV.
Conclusions:Viable candidates for markers of resistance detection for incorporation into diagnostics were demonstrated.
Such tests may enhance antibiotic stewardship and treatment options.
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Received 29 November 2018, accepted 1 April 2019, published online 1 August 2019
Introduction
Patients attending sexual health clinics (SHCs) will often
present with non-specific genital infections, associated with
several common symptoms, resulting from a diverse range of
aetiologies. Effective infection management is therefore highly
dependent on an accurate and rapid diagnosis to inform
prompt treatment. However, this treatment is threatened by
increasing antimicrobial resistance (AMR) rates within sexually
transmitted pathogens,1 exemplified by recent UK reports of
gonorrhoea resistant to azithromycin.2,3
Current diagnostics commonly use nucleic acid amplification
tests (NAATs), favoured due to high sensitivity of detection and a
quicker time to result than culture.4 However, culture remains the
onlymeansofdeterminingAMRprofiles forgonococcal infection,
but its use is in decline and results are often unavailable at time of
diagnosis,meaningempiricalmanagementof genital syndromes is
common.5 Although empirical therapy helps to reduce time to
treatment, onward transmission of infection and the possible
loss to follow up, it also risks induction and further spread of
AMR. Furthermore, it removes the opportunity for recycling of
older antibiotics that are likely to still be effective in many cases,
but are no longer recommended for empirical use.6,7
These challenges could, in part, be addressed by the
development and deployment of NAAT technologies that
identify both infection and AMR susceptibility in the
laboratory and at the point-of-care (PoC), thereby enabling
immediate administration of specific antibiotic therapy when
patients are diagnosed (‘precision medicine’). Calls for such
novel diagnostics have been increasing in response to rising
AMR rates,8,9 yet have been restricted, in part, by incomplete
understanding of the relationship between bacterial genotype
and antimicrobial susceptibility phenotype.
Neisseria gonorrhoeae is a common sexually transmissible
infection (STI), with high rates of AMR.10,11 Fluoroquinolone
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and macrolide antibiotics, which represent both current and
previously recommended treatments for gonorrhoea,11 are
effective in eradicating susceptible strains and are associated
with specific genetic mechanisms of resistance. Macrolides
inhibit protein synthesis by binding bacterial 23S
rRNA. Consequently, mutations associated with resistance
typically centre on alteration of the macrolide binding site,
through mutation or methylation of specific sites in the 23S
rRNA.12 N. gonorrhoeae harbours four copies of the 23S rRNA
allele, and the number of alleles carrying mutations can
rapidly increase under antibiotic selection pressure, assumed
to be a result of internal homologous recombination.13,14
Fluoroquinolones inhibit DNA gyrase and DNA
topoisomerase IV, two enzymes required for DNA
replication, encoded by the gyrA and parC genes
respectively. Specific mutations in the quinolone resistance-
determining regions (QRDR) of these genes are known to
reduce the activity of fluoroquinolones.15,16 Mutations in
genes encoding multi-drug efflux pumps that remove
antibiotics from the bacteria can also influence minimum
inhibitory concentrations (MIC) to varying degrees.17
As part of a body of work developing PoC tests for
fluoroquinolone and macrolide resistance in Mycoplasma
genitalium and N. gonorrhoeae (www.preciseresearch.co.uk),
this review aimed to appraise the literature on AMR genotype
for N. gonorrhoeae in relation to in vitro antimicrobial
susceptibility to fluoroquinolone and macrolide antibiotics.
These antibiotics were selected as they have relatively
simple major mechanisms of resistance and a significant
proportion of circulating gonococcal strains remain
susceptible to them.11 For other antibiotics, such as
cephalosporins, many different resistance mechanisms exist,
affecting multiple genes with multiple mutations,13 making
them more challenging for PoC AMR tests, where the
current state of technology may limit screening to a finite
number of mutations. We aimed to test the strength of
genotypic–phenotypic associations when pooling data from
included publications and to appraise the diagnostic accuracy
of detecting AMR using the identified genotypic markers, in
order to assess their suitability for inclusion on diagnostic
platforms for AMR prediction.
Methods
Publication search strategy and screening criteria
Two separate searches were performed to reflect the aims:
(1) macrolide resistance in N. gonorrhoeae; and (2)
fluoroquinolone resistance in N. gonorrhoeae. Preliminary
review of the literature informed search term format,
including the organism name, region associated with
resistance (e.g. 23S rRNA for macrolides or gyrA and parC
for fluoroquinolones) and a broader component comprising
variations on ‘genotype’ and the target antibiotic. This
approach was used in an effort to ensure more general or
emerging resistance mechanisms could still be detected
(Text S1 available as Supplementary Material to this paper).
Publication screening and data extraction were shared between
C. L. Hall and M. A. Harrison and performed in September
2016 using OvidSP to search both EMBASE and Medline
databases.
Abstracts were screened to determine publication suitability
for inclusion in the review (Table 1), with the full text searched
where necessary. Included publications had to target the
organism of interest and antibiotic of interest, and report
resistance-associated genotype in relation to antibiotic of
interest, with no date restriction applied. Exclusion criteria
were: publications that were not available in the English
language or reviews and conference abstracts where results
Table 1. Number of publications included in the literature review and data analysis following screening of results from the literature search







Number of studies following the literature search, duplicate
deletion and reference and citation checking
688 613
Inclusion criteria not met Targets Neisseria gonorrhoeae 52 49
Discusses macrolide or fluoroquinolone resistance 243 137
Reports resistance-associated genotype in relation to antibiotic
of interest
153 239
Exclusion criteria (literature review) Not available in English language 21 24
Review data (bibliography and citation check still performed if
relevant)
52 22
Conference abstracts where results are listed in a full
publication
1 8
Number of studies in literature review 62 133
Exclusion criteria (data analysis) Studies listing mutations at gene level only (unless resistance is
the result of gene presence. e.g. erm)A
3 8
Non-clinical samples (e.g. laboratory and reference strains)A 10 21
Repeat datasets 7 23
Cannot determine number of isolates for each genotype 0 3
Number of studies in literature review used in data analysis 42 79
AThese included strains selected due to known mutation profiles (e.g. for testing of new methodology or antibiotics).
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were available in full publication. Due to variations in data
provision and quality, further exclusion criteria were applied to
limit publications to those providing the level of detail required
for data analysis of phenotypic–genotypic relationships.
Publications excluded at this stage were limited to the
literature review only and used as a source of additional
information for included papers, especially if two
publications were linked. Exclusion criteria for data analysis
were: mutation listed to gene level only; number of isolates or
samples with each mutation not stated; reference strains and
laboratory strains only; and repeat datasets. Some publications
containing data constituting an exclusion criteria (e.g. reference
strains) were extracted if this was clearly differentiated from the
usable sample set. Publications included for data analysis
(Text S2) and relevant reviews underwent reference and
citation checking.
Data extraction
Optimal data capture from each eligible publication included:
genotyping methodology; coverage and capacity to detect all
mutations [e.g. targeted single nucleotide polymorphisms
(SNPs) or sequencing of relevant gene regions]; whether
samples were randomly selected or stratified by phenotypic
characteristics; in vitro susceptibility phenotype; position of
mutation; new base or amino acid followingmutation; treatment
regimen and dose; and whether the study had pre- and post-
treatment data available. All samples or isolates were treated as
separate cases, except repeat datasets and those identified as
pre- and post- treatment samples (Table S3 and Table S4
available as Supplementary Material to this paper).
If the MIC to several fluoroquinolones or macrolides was
reported, analysis centred on ciprofloxacin and azithromycin
respectively, as these are either in use or have been
recommended for treatment previously. Numbering of
nucleotide bases or amino acid residue positions are in
Escherichia coli numbering for 23S rRNA resistance and
N. gonorrhoeae numbering for fluoroquinolone resistance
and mutations within the mtr locus.
Data analyses
Variation in the level of detail provided in each publication
made comparison of the entire database unreliable, so set
criteria were defined for each analysis (Table 2), with
studies, samples or isolates only included if these were met.
In order to standardise the thresholds for resistance and
susceptibility for isolates of N. gonorrhoeae, the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) guidelines18 were referenced to assign resistance
phenotypes based on MICs described in each publication.
EUCAST guidelines define ciprofloxacin resistance in
N. gonorrhoeae as a MIC > 0.06 mg L1, which was used
for this analysis. However, many studies used 0.06 mg L1 as
a susceptibility threshold; therefore, not differentiating between
intermediate (0.06 mg L1) and sensitive ( 0.03 mg L1)
isolates, as defined by EUCAST. Therefore, all isolates with an
MIC of 0.06mg L1 were assigned as non-resistant. A similar
approach was taken for azithromycin resistance in
N. gonorrhoeae, with a MIC of > 0.5 mg L1 assigned as
resistant and  0.5 mg L1 as non-resistant, with resistant
isolates further categorised as low-level resistant (> 0.5 mg L1
and < 2 mg L1), moderate-level resistant ( 2 mg L1 and
< 256 mg L1) and high-level resistant ( 256 mg L1).
Statistical methods
All statistical analysis was performed in Stata/IC 14 (Stata
Corp, College Station, TX, USA). Both c2 and univariate
logistic regression analyses were performed for macrolide
and fluoroquinolone resistance in N. gonorrhoeae to
determine if presence of a mutation was significantly higher
in isolates or samples with resistant MICs. This was followed by
multivariate logistic regression analyses using univariate
variables at P < 0.05 in a forward stepwise approach to
determine the strength of each genotype as independent
markers of resistance. We chose a 0.05 P-value threshold to
limit the number of variables from chance associations being
selected and considered the biological plausibility of the
variables included (and not included) based on this cut-off.
The correlation between the numbers of mutated 23S rRNA
alleles forN. gonorrhoeae and level of macrolide resistance was
analysed using Spearman’s rank-order correlation coefficient.
Sensitivity and specificity of resistance detection for the
genotypic markers of AMR determined in this review were
calculated using the following definitions: presence of an AMR
marker in resistant isolates as true positive, in non-resistant
isolates as false positive, their absence (wild-type) in non-
resistant isolates as true negative and in resistant isolates as
false negative. Calculated sensitivities and specificities were
applied to the number of N. gonorrhoeae infections and the
prevalence of resistance for 2016 in England and Wales
acquired from Public Health England (PHE) STI and
Gonococcal Resistance to Antimicrobial Surveillance
Program (GRASP) datasets,11,19 to determine positive
predictive values (PPV) and negative predictive values




InN. gonorrhoeae, mutations within domain V of the 23S rRNA
gene, A – G or C – T substitution at A2059 and C2611
respectively, are associated with azithromycin resistance
(P < 0.001). Of the 366 isolates harbouring 23S rRNA
mutations with the specific number of mutated alleles reported,
five were non-resistant and each had only one allele mutated. All
isolates with two or more mutated alleles from this review were
resistant (n = 359) (Table 3).
We found data for 1015 isolates for which the numbers of
23S rRNA mutated alleles were recorded and for which an
azithromycin resistance category (i.e. non-resistant, low-level,
moderate-level and high-level resistant) could be allocated
(Figure 1). A strong correlation was found between MIC and
number of mutated alleles, in isolates whereMIC was defined as
an integer (e.g. not as a range) and the number of mutated alleles
was specifically reported (n = 571, rs = 0.7846; P = < 0.001).
A mutation in L22 was only reported once and mutations in
L4 were not significantly associated with resistance.20
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Methylase (erm) genes, themac efflux pump and ere genes were
investigated, but were either not associated with resistance, very
rare in resistant isolates or present with 23S rRNA mutations or
where no other resistance associated region was typed.
Mutations in the MtrCDE transporter were found in both the




























































































































































































































































































































































































Table 3. Number of mutated alleles of the 23S rRNA gene and
azithromycin resistance in Neisseria gonorrhoeae











isolates: n = 469 (%)
0 185 (33.9) 464 (98.9)
1 2 (0.4) 5 (1.1)
2 21 (3.8) 0
3 26 (4.8) 0

























Fig. 1. Level of azithromycin resistance with number of mutated 23S
rRNA alleles in Neisseria gonorrhoeae. Only isolates that could be
categorised into macrolide resistance levels are included in the figure
(n = 1015). Non-resistant: MIC  0.5 mg L1; LoLR, low-level
resistance: MIC > 0.5 mg L1 and < 2 mg L1; MoLR, moderate-level
resistance: MIC  2 mg L1 and < 256 mg L1; HiLR, high-level
resistance: MIC  256 mg L1. Spearman rank correlation coefficient
(rs) between actual MIC and number of mutated alleles = 0.7846;
P = 0.0000005 (n = 571). MIC, minimum inhibitory concentration.
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identified at 20 positions within the MtrR, but only mutation at
G45 was associated with resistance (P < 0.05). Alterations to
amino acid position 105 inMtrR were omitted from the analysis,
as the reference strains to which the isolates under analysis were
being compared differed in the amino acid at this position,
between histidine and tyrosine. This resulted in some studies
considering H105 as wild-type whereas others considered Y105
as wild-type (Text S2). The 23S rRNA and G45 mutations could
not be assessed together in multivariate logistic regression
analysis, as in the sample set qualifying for this analysis; G45
mutations alone were no longer significantly associated with
resistance. Furthermore, mutations at G45 were only present in
17.9% (145/812) of all resistant isolates screened.
Included publications described several rare alterations to
themtr promoter region including: aNeisseria meningitidis-like
promoter; mosaic promoter; and a range of insertions, deletions
and substitutions. Most frequently reported alterations were an
adenine deletion (DelA), a thymidine insertion and an adenine-
to-cytosine substitution within the mtr promoter region, but
these changes were found in several both resistant and non-
resistant isolates, and none were determined to be independent
markers of resistance by univariate analysis.
Consequently, this review only indicated the A2059G and
C2611Tmutations within the 23S rRNA gene to be independent
markers of azithromycin resistance, with higher levels of
resistance more likely with increasing numbers of mutated
alleles. However, the independent role of MtrR mutations on
resistance could not be discounted. As a diagnostic marker of
azithromycin resistance, use of the presence of either C2611T or
A2059G 23S rRNA mutations (n = 1015) within at least one
allele gave a sensitivity and specificity of 66.1% (95% CI
62.1 – 70.0%) and 98.9% (95% CI 97.5 – 99.5%)
respectively; when mutations in two or more alleles were
used, this gave 65.8% (95% CI 61.7 – 69.6%) and 100%
(95% CI 99.2 – 100%) respectively. When presence of either
at least one mutated 23S rRNA allele or the MtrR mutation at
G45 was considered, in a smaller sample set of 613, sensitivity
was 60.9% (95% CI 56.0 – 65.7%) and specificity 89.6% (95%
CI 85.6 – 93.6%). The sensitivity and specificity of the
combined putative diagnostic was applied to the 36 24419
diagnoses of gonorrhoea made in England and Wales in
2016, using a prevalence of macrolide resistance (MIC > 0.5
mg L1) of 10%.11 This gave a PPV of 39.5% (95% CI
38.2 – 40.8%) and a NPV of 95.4% (95% CI 95.1 – 95.6%).
However, when applying the lower margin of the 95% CI of
sensitivity and specificity estimates, a PPV and NPV of 30.2%
(95% CI 29.1 – 31.3%) and 94.6% (95% CI 94.3– 94.9%) were
obtained respectively. Interestingly, applying the lower margins
of accuracy of at least one 23S rRNA mutant allele to this same
dataset gave a PPV and NPV of 73.6% (95% CI 72.0 – 75.2%)
and 95.9% (95% CI 95.6 – 96.1%) respectively.
Fluoroquinolone resistance
Studies investigating fluoroquinolone resistance sequenced the
QRDR for gyrA and parC, encoding the major subunits of DNA
gyrase and DNA topoisomerase IV respectively.15 The minor
subunits of these proteins, encoded by gyrB and parE
respectively, were investigated in some cases and mutations
detected. No mutations were found in gyrB, and in parE
mutations were only present in isolates also harbouring gyrA
mutations.
Neisseria gonorrhoeae isolates frequently harboured
multiple mutations in both genes, with a total of seven and
nine amino acid changes within the QRDR of gyrA and parC
respectively. Of these, mutations at S91 and D95 from gyrA and
D86 and S87 from parC were significantly higher in resistant
isolates (P < 0.05), with wild-type S88 and E91 always found in
non-resistant isolates. Mutations at other residues were present
in less than 1% of the total number of resistant isolates where the
QRDR was typed. Importantly, only one resistant isolate
harboured a parC mutation (E91G) without an S91 and or
D95 mutation in gyrA. Multivariate analyses revealed only
S91 and D95 to be significantly associated with resistance,
with 98.5% of resistant isolates harbouring one or both of these
mutations (Table 4). Of those isolates with an S91 and
D95 genotype and accompanying phenotypic susceptibility,
2.5% of resistant and 5.6% of non-resistant isolates
harboured a D95 mutation only. Within this same sample set
but using only those isolates where S91 is wild-type,
D95 mutations were found in 64% of resistant isolates as
opposed to 5.6% of non-resistant isolates. When used
together, diversion from the wild-type at S91 or D95 gave a
98.6% (95% CI 98.0 – 99.0%) sensitivity and 91.4% (95% CI
88.6 – 93.7%) specificity for resistance detection.
The GRASP report for 2016 uses a MIC of  1.0 mg L1 as
the definition for ciprofloxacin resistance.11 As the EUCAST
MIC of > 0.06 mg L1 definition was used in this review, the
29% prevalence of resistance fromGRASP could not be applied
to the 36 244 gonococcal diagnoses reported in England and
Wales in 2016.19 However, speculating a resistance prevalence
of 50% by our definition is not unreasonable, and applying the
lower 95% CI margins of sensitivity and specificity to
the dataset gives a PPV and NPV of 89.5% (95% CI
89.1 – 90.0%) and 97.7% (95% CI 97.5 – 98.0%) respectively.
As with macrolide resistance, the MtrCDE efflux pump was
investigated for association with ciprofloxacin resistance in
N. gonorrhoeae, although in fewer studies. Of the 10
mutations reported within MtrR, only the G45D polymorphism
wassignificantlyhigher in resistant isolates (P<0.001), aswas the
DelA mtr promoter mutation (P < 0.001). When S91, G45 and
DelA were assessed together in a multivariate analysis, only
mutations at S91 remained significantly associated with
resistance.
Table 4. Mutations within DNA gyrase at codons S91 and D95 and
association with fluoroquinolone resistance in Neisseria gonorrhoeae
Data are presented as n (%)
gyrA S91 and D95 genotype and ciprofloxacin
susceptibility (n = 2678)
Genotype Number of resistant
isolates
(%): n = 2211
Number of non-resistant
isolates
(%): n = 467
S91 and D95 mutation 1702 (77.0) 6 (1.3)
S91 mutation only 421 (19.0) 8 (1.7)
D95 mutation only 56 (2.5) 26 (5.6)
Wild-type at both residues 32 (1.5) 427 (91.4)
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Discussion
The spread of antimicrobial resistance threatens to undermine
management of many infectious diseases. Interventions
proposed to address this challenge include a more intelligent
use of antibiotics, partly enabled by novel diagnostic
technologies that can predict AMR rapidly.1 These promise
more accurate treatments and the potential to recycle older
antibiotics, thus improving antibiotic stewardship.21 In this
review, we sought to appraise the literature for genotypic
candidates associated with macrolide and fluoroquinolone
resistance to N. gonorrhoeae and assess the potential
accuracy of these candidate markers if included in AMR
diagnostic platforms.
In N. gonorrhoeae, fluoroquinolones have been largely
discontinued for empirical therapy because of high levels of
resistance globally, yet in many regions a large proportion of
gonococcal strains remain phenotypically susceptible to
ciprofloxacin.11 Our analysis confirmed the central role of
two mutations in the gyrA gene, representing amino acid
changes at S91 and D95, which were both independently
predictive of ciprofloxacin resistance. The data in this review
gave a combined S91 and D95 diagnostic a sensitivity and
specificity of 98.6% (95% CI 98.0 – 99.0%) and 91.4% (95% CI
88.6 – 93.7%) respectively, for detection of ciprofloxacin
resistance. In order to get a sense of the effect of use of
these tests in clinical practice, we applied the lower 95% CI
margins of sensitivity and specificity to the 36 244 gonococcal
diagnoses reported in England and Wales in 2016. These gave a
PPV and NPV of 89.5% (95% CI 89.1 – 90.0%) and 97.7%
(95% CI 97.5 – 98.0%) respectively. This would imply a 97.7%
chance of having a ciprofloxacin-susceptible infection if these
markers were wild-type. In this virtual scenario, of the 18 122
ciprofloxacin ‘non-resistant’ diagnoses of gonorrhoea, the S91
and D95 diagnostic test would potentially identify 16 047. The
test would also report approximately 370 diagnoses to be
genotypically ‘non-resistant’ when, in fact, phenotypically
resistant, making such patients at risk of being given
ciprofloxacin when they have a ciprofloxacin-resistant
infection. This is an important clinical risk to minimise, and
perhaps a related question to resolve would be at what NPV
would it be better to give ciprofloxacin in combination with
another antibiotic as opposed to risk monotherapy.
Furthermore, among the 2016 cohort, ~2075 genotypically
resistant infections would, in fact, be phenotypically non-
resistant. This second error represents both missed
opportunities to identify patients for whom ciprofloxacin
could be used and diagnostic test wastage. Clearly, these
predictions are dependent on the availability of an AMR
genotypic result at the point of diagnosis before treatment,
population prevalence of resistance, as well as the molecular
accuracy of marker detection. Evaluating these diagnostic
approaches prospectively for accuracy, cost-effectiveness and
effect on resistance spread will be an important factor in future
development, in order to minimise the risks identified above.
However, the data suggest that an S91 and D95 gyrA diagnostic
may well be of value, even in particularly high ciprofloxacin
resistance prevalence settings, but more work on the
determinants of resistance is required to improve both
sensitivity and specificity.
Although critical for resistance in E. coli, the D95 mutation
was reported in borderline ciprofloxacin-resistant
N. gonorrhoeae in transformation studies or when induced
in vitro, but the MIC was 16-fold greater than the wild-type
parental strain.22,23 Of those isolates wild-type at S91 and
resistant in this review, 64% carried a mutation at D95,
compared with just 5.6% in non-resistant strains, with
inclusion of D95 raising sensitivity of detecting AMR from
96.0% (95% CI 95.1 – 96.8%) to 98.5% (95% CI 98.0 – 99.0%).
Inclusion of D95 reduces specificity from 97.1% (95%CI 95.2 –
98.3%) to 91.4% (95%CI 88.6 – 93.7%), meaning more isolates
will be labelled resistant when in fact non-resistant, but as
ciprofloxacin is no longer recommended for treatment of
N. gonorrhoeae, these people would not have received this
treatment anyway, highlighting this as an added value approach.
In this review, we demonstrated a clear association between
23S rRNA mutations at positions A2059 and C2611 and
azithromycin resistance in N. gonorrhoeae, particularly if
two or more alleles of the mutated gene were carried.
Although the sensitivity of using 23S rRNA markers for
detecting azithromycin resistance was only 66.1%, this could
be explained by the association of mutated alleles with moderate
or high-level resistance, combined with the fact that a
significant proportion of resistant samples were low-level
resistant (Figure 1). Increased azithromycin MICs in relation
to increasing numbers of mutated 23S rRNA alleles has been
reported previously in N. gonorrhoeae and other species
harbouring multiple copies of the 23S rRNA gene.14,24 Each
gene copy encodes for a 23S rRNA protein, with the likely
mechanism of phenotypic resistance occurring when a single
mutated 23S rRNA gene drives the same mutations in the other
copies through a process of internal recombination, reducing the
proportion of antibiotic susceptible 23S rRNA protein
available.14
Applying the lower margin of the 95% CI of sensitivity and
specificity estimates to the 36 24419 diagnoses of gonorrhoea
made in England and Wales in 2016 gave a PPV and NPV of
30.2% and 94.6% respectively, for a combined 23S–G45 test.
Interestingly, applying the lower margins of accuracy of at
least one 23S rRNA mutant allele to this same dataset gave a
PPV and NPV of 73.6% and 95.9% respectively. For clinicians,
the estimates suggest that for azithromycin resistance, some
value may be obtained by using the 23S rRNA markers alone to
identify azithromycin susceptible cases genotypically, but that
this would come at a significant cost in terms of test wastage as a
result of misidentifying susceptible cases as resistant. As with
ciprofloxacin, how azithromycin might be used with a 23S
rRNA only test could be explored, perhaps, for example, using it
in combination therapies and at high doses (Figure 1)
following a negative test, as our findings demonstrate that
high-level resistance is effectively ruled out. However, such
an approach should give caution because of the number of
moderate-level resistant infections in this group. Again,
further work to better understand the genotypic–phenotypic
relationships of macrolide AMR may improve the accuracy
of predictions. The lack of consensus between the different
reference strains used by studies, in terms of the amino acid at
position 105 within MtrR, prevented further analysis of this
mutation. Uniform agreement on the wild-type and mutant
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genotype at this position would allow further analysis and
support better understanding of this residue in relation to
azithromycin resistance.
Overexpression of MtrCDE can increase MIC to
macrolides13,17 and has been associated with fluoroquinolone
resistance when in combination with gyrA or parC
mutations.25,26 However, this review found mutations within
MtrCDE and its promoter unreliable as targeted independent
markers of azithromycin and ciprofloxacin resistance due to
their prevalence in non-resistant isolates or association with
more definitive resistance markers such as S91. This
demonstrates the complicated nature of designing AMR
detection systems when several mechanisms can influence
the resistance phenotype, and a limitation of using specific
targets for resistance detection. Alternative methods such as
sequencing may be able to screen several regions associated
with resistance and use a wild-type genotype across the entire
region as a marker of susceptibility. Furthermore, variation in
MIC reporting necessitated resistance cut-offs, which may
mean smaller borderline increases or intermediate MICs
associated with certain resistance mechanisms, are missed.
Rapid NAAT diagnostics have been integrated into SHC
clinical care pathways,27 but in the UK, there remains no
licenced diagnostic for dual detection of infection and
susceptibility at the PoC, although these are under
investigation; for example, the Precise study (www.
preciseresearch.co.uk) and the SpeeDx assay (https://plexpcr.
com/resistanceplus-gc/). Furthermore, use and trials of
laboratory detection of fluoroquinolone resistance in
N. gonorrhoeae are underway.28 However, implementation
and technology choice for the detection of resistance markers
presents a series of challenges. SNP-based resistance detection
may require coverage of multiple alleles, such as the 23S rRNA
region in N. gonorrhoeae,13 or account for the occurrence of
synonymous SNPs to avoid false calling of resistant isolates.
Test efficacy is also highly dependent on active surveillance
programs, monitoring patterns of resistance and associated
genotypes, ideally on a global scale to capture the influence
of regional differences in antibiotic usage.
This review provides a critical appraisal of genetic
determinants of resistance to fluoroquinolones and
macrolides in N. gonorrhoeae; however, data reporting
varied widely between publications, with differences in both
resistance mechanisms and specific mutations tested.
Furthermore, as MIC cut-offs used for classification of
phenotypic resistance vary globally, we selected resistance
cut-offs based on EUCAST guidelines and developed clear
criteria for data inclusion in each analysis. However, data
collected from these studies are still subject to common
limitations, including sensitivity and specificity of molecular
tests, particularly for studies investigating new methods for
resistance detection, although the majority of publications used
sequencing or established PCR-based assays. In consideration
of this, we used the lower CIs of sensitivities and specificities to
calculate conservative PPV and NPV estimates.
We were also limited to using in vitroMIC as the measure of
resistance to the antibiotic of interest, as this is the most
common means of reporting antibiotic susceptibility in
N. gonorrhoeae. As in vitro AMR does not necessarily
equate to treatment failure, increased reporting of treatment
response data alongside in vitro susceptibility testing would be
important to future work assessing the utility of these markers
for clinical impact.
Molecular detection of antibiotic resistance offers the
potential to significantly enhance NAAT diagnostics.
Providing susceptibility profiles at the PoC enables a more
prompt and accurate treatment, an invaluable tool in aiding
antibiotic stewardship and a key approach to reduction of
AMR. However, such tests should be used to enhance testing
and be performed in conjunction with culture and sequencing to
monitor susceptibility profiles and circulating and emerging
genotypes.
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